TY - JOUR
T1 - Towards a classification of biomarkers of neuropsychiatric disease
T2 - From encompass to compass
AU - Davis, J.
AU - Maes, M.
AU - Andreazza, A.
AU - McGrath, J. J.
AU - Tye, S. J.
AU - Berk, M.
N1 - Funding Information:
MB is supported by a NHMRC Senior Principal Research Fellowship 1059660, and has received grant support from NIH, Simons Autism Foundation, Cancer Council of Victoria, CRC for Mental Health, Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma and Servier. JJM is supported by NHMRC John Cade Fellowship 1056929. AA is supported by Brain and Behaviour Foundation (NARSAD) and the Canadian Institute of Health Research. SJT is supported by the State of Minnesota.
Publisher Copyright:
© 2015 Macmillan Publishers Limited.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - There is currently considerable imprecision in the nosology of biomarkers used in the study of neuropsychiatric disease. The neuropsychiatric field lags behind others such as oncology, wherein, rather than using 'biomarker' as a blanket term for a diverse range of clinical phenomena, biomarkers have been actively classified into separate categories, including prognostic and predictive tests. A similar taxonomy is proposed for neuropsychiatric diseases in which the core biology remains relatively unknown. This paper divides potential biomarkers into those of (1) risk, (2) diagnosis/trait, (3) state or acuity, (4) stage, (5) treatment response and (6) prognosis, and provides illustrative exemplars. Of course, biomarkers rely on available technology and, as we learn more about the neurobiological correlates of neuropsychiatric disorders, we will realize that the classification of biomarkers across these six categories can change, and some markers may fit into more than one category.
AB - There is currently considerable imprecision in the nosology of biomarkers used in the study of neuropsychiatric disease. The neuropsychiatric field lags behind others such as oncology, wherein, rather than using 'biomarker' as a blanket term for a diverse range of clinical phenomena, biomarkers have been actively classified into separate categories, including prognostic and predictive tests. A similar taxonomy is proposed for neuropsychiatric diseases in which the core biology remains relatively unknown. This paper divides potential biomarkers into those of (1) risk, (2) diagnosis/trait, (3) state or acuity, (4) stage, (5) treatment response and (6) prognosis, and provides illustrative exemplars. Of course, biomarkers rely on available technology and, as we learn more about the neurobiological correlates of neuropsychiatric disorders, we will realize that the classification of biomarkers across these six categories can change, and some markers may fit into more than one category.
UR - http://www.scopus.com/inward/record.url?scp=84937717957&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937717957&partnerID=8YFLogxK
U2 - 10.1038/mp.2014.139
DO - 10.1038/mp.2014.139
M3 - Review article
C2 - 25349167
AN - SCOPUS:84937717957
SN - 1359-4184
VL - 20
SP - 152
EP - 153
JO - Molecular Psychiatry
JF - Molecular Psychiatry
IS - 2
ER -